Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs Merck & Co., Inc. — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $61.07 (market cap $44.49B), while Merck & Co., Inc. trades at $146.32 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 7.9× JPMorgan Nasdaq Equity Premium Income ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 65 Days and Merck & Co., Inc. for 98 Days on average.
| JEPQ | MRK | |
|---|---|---|
Market Cap | $44.49B | $351.28B |
Volume | 5,681,789 | 7,969,665 |
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $156.43 |
52-Week Low | $53.77 | $82.49 |
Typical Hold Time | 65 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $61.03, down 0.39% on the day, with a bullish technical signal from moving averages despite neutral oscillators. The ETF maintains strong income generation through its covered-call strategy, with recent dividends ranging from $0.57 to $0.70 per share. Financial media coverage highlights JEPQ's 11% estimated annualized yield and suitability for retirement income, though analysts note the trade-off between high current income and limited price appreciation potential.
JEPQ offers exceptional current income for investors seeking monthly cash flow, with its covered-call strategy performing well in volatile markets. However, the ETF faces risks from market volatility dependence and potential principal erosion if yield chasing outweighs total return considerations. Institutional interest remains strong, with Envestnet increasing its position by 8.2% recently.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
